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ABSTRACT 
Patients with chronic kidney disease (CKD) have a high risk of cardiovascular 
morbidity and mortality. Adding to traditional risk factors, e.g., Framingham risk 
factors, novel risk factors including inflammation, insulin resistance (IR) and metabolic 
syndrome (MetS) are being detected in patients with advanced CKD. Previous research 
demonstrates a promising possibility of improving patient outcomes by dietary 
manipulation, which could be an essential part of multi-faceted interventions. This 
thesis tries to increase our understanding of circulating fatty acids as a reflection of 
dietary intake in patients with CKD, with special emphasis on their clinical 
determinants and outcome implications. 
 
Study 1 identifies fatty acids in serum cholesterol esters and adipose tissue that are 
adequate biomarkers of habitual intake in CKD. We found that linoleic acid (LA), 
eicosapentaenoic acid, docosahexaenoic acid, and palmitic acid in serum cholesterol 
esters and adipose tissue are good indicators of the habitual dietary fat intake in elderly 
men with CKD. Dietary fish intake reflects well the intake of n-3 polyunsaturated fatty 
acids (PUFA) of marine origin. 
 
Study 2 investigates the implications of circulating essential PUFA, as a reflection of 
long-term dietary intake, on the inflammatory risk profile and clinical outcome of 
dialysis patients. LA in plasma phospholipids is inversely associated with interleukin-6 
and all-cause mortality in dialysis patients. Associations between n-3 PUFA, 
inflammation and mortality were not observed. 
 
Study 3 investigates clinical determinants and outcome implications of estimated 
stearoyl-CoA desaturase-1 (SCD-1) activities of the liver and adipose tissue, as 
indicators of saturated fat intake, in dialysis patients. We found that both hepatic and 
adipose tissue SCD-1 activity indices independently relate with interleukin-6 and 
predict mortality in dialysis patients. 
 
Study 4 assesses cross-sectional relationships between serum fatty acid patterns, MetS, 
IR and inflammation in CKD. A serum fatty acid pattern reflecting low LA and high 
saturated fatty acids strongly associates with MetS, IR and C-reactive protein, while 
another pattern reflecting high n-3 PUFA is not linked with these risk factors, in two 
independent cohorts of elderly individuals with CKD. 
 
Keywords: chronic kidney disease; competing risk; dialysis; factor analysis; 
inflammation; linoleic acid; mortality; n-3 polyunsaturated fatty acids; saturated fatty 
acids; stearoyl-CoA desaturase-1. 
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1 INTRODUCTION 
1.1 CHRONIC KIDNEY DISEASE 
Chronic kidney disease (CKD), usually defined as albuminuria and/or decreased 
glomerular filtration rate (GFR),
1,2
 is highly prevalent worldwide and is recognized as 
a threat to public health.
3,4
 Epidemiological studies demonstrate that the prevalence of 
CKD has reached epidemic proportions affecting 10–13% of the populations in many 
countries.
5-12
 As shown in a systematic review, CKD is age related: While 7.2% of 
subjects older than 30 years have CKD, the prevalence ranges from 23.4% to 35.8% 
in those older than 64 years.
13
 
 
One potential outcome of CKD is end-stage renal disease (ESRD),
14
 which requires 
renal replacement therapy in the form of hemodialysis (HD), peritoneal dialysis (PD), 
or kidney transplantation. However, even before developing ESRD, CKD patients are 
at a strikingly increased risk for hospitalization and premature death,
15
 in particular 
from cardiovascular causes,
16-18
 thus strongly linking CKD to cardiovascular disease 
(CVD).
19
 Moreover, CKD is accompanied by extremely high morbidity, low quality of 
life, decreased productivity, family pressure, mental disorders and high costs.
4
 
 
Motivated by the dismal outcomes associated with CKD, a number of randomized 
controlled trials (RCT) have been conducted in this vulnerable population. Evidence 
has shown the efficacy of a few management options for CKD. For instance, control of 
hypertension and proteinuria with angiotensin-converting-enzyme inhibitors reduces 
risk of progression to ESRD;
20,21
 reduction of low-density lipoprotein (LDL) lowers 
cardiovascular risk;
22,23
 antioxidants prevents cardiovascular events in HD patients;
24,25
 
and frequent HD treatment results in a better survival rate.
26
 Nevertheless, the past two 
decades have unfortunately also witnessed many more RCT failing to show a survival 
benefit of new treatment strategies in CKD patients, such as planned early initiation of 
dialysis,
27
 increased dialysis dose,
28,29
 online hemodiafiltration,
30
 intensified nutrition,
31
 
homocysteine lowering therapy,
32,33
 normalization of hemoglobin with 
erythropoietin,
34-36
 lipid lowering with statins,
37,38
 treatment with angiotensin-
converting-enzyme inhibitors or calcium channel blocker,
39,40
 and correction of 
secondary hyperparathyroidism.
41,42
  
 
The reasons for such frustrating results have not been fully elucidated, and it is possible 
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that the risk profile is different in CKD compared with the general population. Adding 
to traditional risk factors, e.g., Framingham risk factors (age, male sex, obesity, 
smoking, hypertension, dyslipidemia, and diabetes), novel risk factors are being 
detected in patients with advanced CKD and may contribute to our efforts in 
identifying the real cardiovascular culprits.
43
 These factors include persistent 
inflammation,
44
 protein-energy wasting (PEW),
45
 metabolic syndrome (MetS),
46
 insulin 
resistance (IR),
47
 endothelial dysfunction,
48
 oxidative stress,
49
 and vascular 
calcification.
50
 Each of these is not only highly prevalent in CKD but also more 
strongly linked to CVD than in the general population.
43
 Causal relationships between 
these new markers and CVD in CKD patients remain to be established. 
 
1.2 DIETARY FATS IN CHRONIC KIDNEY DISEASE 
Food is ingested and assimilated by humans in an effort to produce energy, maintain 
life, or stimulate growth. Hippocrates once said “Let thy food be thy medicine & thy 
medicine be thy food”. Researchers recognize unique health benefits of individual 
nutrients/dietary patterns as a whole. Observational and interventional evidence in 
CKD has shown favorable implications of a healthy diet on GFR,
51,52
 blood pressure,
53
 
metabolic acidosis,
52,54-56
 nutritional status,
52
 and inflammation.
57
 Although 
confirmation in large RCT is needed, these preliminary findings suggest a promising 
possibility of improving patient outcomes by dietary manipulation, which can at least 
be an essential part of multi-faceted interventions.
58
 
 
Whereas limited evidence supports that reduction in total dietary fat intake per se can 
decrease CVD, replacement of dietary saturated fat and trans-fat with unsaturated fat 
has been recommended for prevention of CVD in the general population.
59
 Earlier 
studies indicate that the dietary content of polyunsaturated fatty acids (PUFA) is often 
decreased in HD patients.
60,61
 Also, HD patients consume fish, a major source of 
eicosapentaenoic acid (EPA; 20:5 n-3) and docosahexaenoic acid (DHA; 22:6 n-3), in 
quantities far below American Heart Association (AHA) recommendations,62 and the 
levels of n-3 PUFA in HD patients are lower than in non-CKD controls.63 On the other 
hand, the majority of HD patients consume too much fat - particularly saturated fatty 
acids (SFA) - in their diets.
64-66
 As apparent from these studies, suboptimal dietary fat 
quality seems common in CKD patients and this may contribute to the CVD risk profile. 
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1.3 FATTY ACIDS: GENERAL CONSIDERATIONS 
A fatty acid is a carboxylic acid with a long aliphatic chain. There are three main types 
of fatty acids in humans: SFA, monounsaturated fatty acids (MUFA), and PUFA. The 
latter two are further classified into n-3, n-6, and n-9 (or omega-3, -6, and -9) 
subfamilies, depending on the location of first double bond counting from the terminal 
methyl carbon toward the carbonyl carbon.
67
 The structure of several common fatty 
acids is shown in Figure 1. 
 
Figure 1. Three dimensional 
representations of several fatty 
acids. 
 
 
 
 
 
 
 
 
 
 
 
Fatty acids have multiple biological functions. During fasting, free fatty acids (FFA; the 
non-esterified form) are released from triacylglycerols to provide an efficient source of 
energy, yielding large quantities of ATP.
68,69
 FFA can act as second messengers 
required for the translation of external cellular signals. Within cells, fatty acids can act 
to amplify or modify signals that control enzyme activities. FFAs are also involved in 
regulating gene expression.
70
 Such effects can be highly specific to particular fatty 
acids. On the other hand, esterified fatty acids are the basic building blocks of lipids, 
e.g., phospholipids, and confer distinctive and crucial physical and metabolic properties 
to the latter. In particular, the presence of SFA and unsaturated fatty acids ensures that 
there is a proper balance between rigidity and flexibility of the cell membranes.
71
 In 
addition, there are more dynamic functions of fatty acids, e.g., anti-inflammatory 
effects.
72,73
 
 
Major dietary sources of fatty acids are summarized in Table 1. Linoleic acid (LA; 
18:2 n-6) and alpha-linolenic acid (ALA; 18:3 n-3) are essential fatty acids that cannot 
be synthesized endogenously by mammals and therefore must be obtained from the diet. 
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Table 1. Major dietary sources of fatty acids. 
Note: *, presented as C:D n-x. C is the number of carbon atoms and D is the number of 
double bonds in the fatty acid. A double bond is located on the x
th
 carbon-carbon bond, 
counting from the terminal methyl carbon toward the carbonyl carbon.
67
 
 
Both EPA and DHA are long-chain n-3 PUFA of marine origin. Although they can be 
synthesized from dietary ALA via elongation and desaturation endogenously, the 
efficiency of the conversion from ALA to EPA/DHA is rather poor.
74,75
 SFA and 
MUFA are considered non-essential fatty acids, because apart from dietary input, they 
can be synthesized by de novo lipogenesis, elongation and desaturation.76 
 
1.4 METHODOLOGY TO EVALUATE FATTY ACID INTAKE 
There are various methods used to evaluate dietary intake of fatty acids in nutritional 
epidemiology. Dietary assessment methods have several limitations that may weaken 
both the accuracy and precision of the measurement, such as under-reporting of 
respondents,
77
 interviewer bias, and lack of well-matched food composition 
databases.
78
 Alternatively, fatty acid biomarkers in blood or tissues could be accurate 
and convenient for estimating long-term dietary fatty acid intake.
78
 Previous studies in 
Common name Chemical 
structure
*
 
Dietary sources 
Saturated fatty acids   
Palmitic acid 16:0 Meats, cheeses, butter, palm oil 
Stearic acid 18:0 Animal fat, cocoa butter and shea 
butter 
Monounsaturated fatty acids 
  
Palmitoleic acid 16:1 n-7 Macadamia oil, sea buckthorn oil 
Oleic acid 18:1 n-9 Sunflower oil, safflower oil 
Polyunsaturated fatty acids 
  
n-6 subfamily   
Linoleic acid 18:2 n-6 Sunflower seed, corn, soya, sesame, 
canola, safflower and their oils 
Gamma-linolenic acid 18:3 n-6 Evening primrose oil 
Dihomo-gamma-linolenic 
acid 
20:3 n-6 Meats, chicken 
Arachidonic acid 20:4 n-6 Meat, eggs 
n-3 subfamily 
  
Alpha-linolenic acid 18:3 n-3 Rapeseed, soybeans, walnuts, 
flaxseed, perilla, chia, hemp and 
their oils 
Eicosapentaenoic acid 20:5 n-3 Oily fish, seafood, seaweed, krill oil, 
seal oil 
Docosapentaenoic acid 22:5 n-3 Seal meat and oils 
Docosahexaenoic acid 22:6 n-3 Oily fish, seafood, seaweed, krill oil, 
seal oil 
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many populations have suggested that fatty acid proportions in serum cholesterol esters, 
phospholipids, as well as adipose tissue are good indicators of the corresponding 
habitual intake of fatty acids of exogenous origin, including EPA and DHA.
79-81
 
However, results regarding the effect of chronic disease status (CVD, hypertension, 
diabetes) on diet-biomarker correlations are mixed.
79,81
 
 
Because both dietary intake and biomarkers of fatty acid intake are associated with 
GFR in community studies,
82,83
 it is conceivable that renal diseases may modify these 
associations. Although some studies in CKD patients have used serum fatty acids as 
biomarkers of dietary intake,
62,84
 it is presently unknown if these biomarkers validly do 
so in the context of CKD. This issue is further developed in Study I. 
 
1.5 FATTY ACIDS AND INFLAMMATION 
The inflammatory process is modulated by various mediators, including compounds 
generated from fatty acid precursors. n-3 PUFA have been investigated in vitro, in vivo, 
and in clinical studies and considered to exert pleiotropic anti-inflammatory properties 
in several diseases.
85
 Eicosanoids are pro-inflammatory signaling molecules derived 
from either n-6 or n-3 PUFA. The eicosanoids derived from n-3 PUFA are less pro-
inflammatory than those derived from the n-6 family.86,87 Additional anti-inflammatory 
effects of n-3 PUFA include attenuation of endothelial adhesiveness, activation of 
leukocytes and resident macrophages, leukocyte-endothelial interaction, leukocyte 
transmigration, and the release of substances that lead to tissue injury.
85
 Conversely, 
SFA can directly cause inflammation; they increase the expression and secretion of 
inflammatory cytokines
88-90
 and induce nuclear factor-kappa B activation.
91
 
 
Given the evidence relating CKD to persistent low-grade inflammation,
92,93
 some 
observational studies have investigated the link between PUFA and inflammation in 
CKD patients. Whereas observational evidence does not show an association between 
n-3 PUFA and inflammation in dialysis subjects,94 several RCT, as summarized in 
Table 2, have shown that supplementation with n-3 PUFA nevertheless has the 
potential to reduce inflammatory markers in CKD patients.
61,95-103
 Even though the 
latent anti-inflammatory property of n-6 PUFA, specifically LA, has been suggested in 
the general population,
104-107
 data in CKD are so far rare.
96
 The association between 
these essential fatty acids and inflammation in dialysis patients and patients with 
moderate CKD is further explored in Study 2 and Study 4, respectively. 
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Table 2. Randomized controlled trials of n-3 polyunsaturated fatty acid 
supplementation on inflammation in chronic kidney disease patients sorted by 
chronological order. 
Note: *, in the interventional group. Abbreviations: CKD, chronic kidney disease; CRP, 
C-reactive protein; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HD, 
hemodialysis; IL, interleukin; LTB, leukotriene B; PGE, prostaglandin E; PUFA, 
polyunsaturated fatty acids; sICAM-1, soluble intercellular adhesion molecule type 1; 
WBC, white blood cells. 
 
Non-essential fatty acids are subject to endogenous conversion, the process of which is 
catalyzed by elongases and desaturases.
109
 Among them, stearoyl-CoA desaturase 
(SCD)-1, expressed both in the liver and adipose tissue, converts dietary or de novo 
SFA into MUFA and is regulated by feedback inhibition (Figure 2).
110-112
 Thus, 
elevated SCD-1 activity signifies excess SFA intake. It has been reported that SCD-1 
activity decreases after feeding with n-6 PUFA.113,114 Indeed, increased SCD-1 activity 
has been implicated in various risk factors including inflammation.
104,105
 However, the 
Study Patients
*
 Duration Intervention Outcome 
Peck et al.61 n=8, HD 8 weeks Capsules, 6 g/d 
fish oil 
↑ PGE2 (0.10 > 
P > 0.05) 
Lossl et al.95 n=8, HD 12 weeks Capsules, 5.2 g/d 
n-3 PUFA 
↓ LTB4 
↑ LTB5 
Begum et 
al.96 
n=12, HD 16 weeks Capsules, 4.4 g/d 
n-3 PUFA 
↓ LTB4 
Saifullah et 
al.97 
n=15, HD 3 months Capsules, 1.3 g/d 
n-3 PUFA 
↓ CRP 
Madsen et 
al.98 
n=22, CKD 
stages 3-4 
8 weeks Capsules, 2.4 g/d 
n-3 PUFA 
↓ CRP (P=0.06) 
Moreira et 
al.99 
n=31, HD 
with CRP < 
50 mg/L 
8 weeks A canned sardine 
sandwich/HD 
session (3 times 
per week) 
↓ CRP only in 
sensitivity 
analyses 
Himmelfarb 
et al.100 
n=31, HD 8 weeks Capsules, 0.8 g/d 
DHA 
↓ IL-6, WBC, 
neutrophil fraction 
of WBC 
Ewers et 
al.101 
n=40, HD 2x6 weeks 
(crossover 
trial) 
Capsules, 3 g/d n-
3 PUFA 
↓ CRP 
Bowden et 
al.102 
n=18, HD 6 months Soft-gel pills, 0.96 
g/d EPA and 0.6 
g/d DHA 
↓ CRP 
Kooshki et 
al.108 
n=17, HD 10 weeks Capsules, 1.24 g/d 
EPA and 0.84 g/d 
DHA 
↓ sICAM-1 
Daud et al.103 n=32, HD 
with serum 
albumin < 39 
g/L 
6 months Capsules, 1.8 g 
EPA and 0.6 g 
DHA/HD session 
(3 times per week) 
No effect on CRP 
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role of SCD-1 in uremic inflammation has not yet been studied. This issue is further 
developed in Study 3. 
 
 
Figure 2. Regulation of monounsaturated fatty acid/saturated fatty acid balance in 
mammalian cell lipids by stearoyl-CoA desaturase-1. Abbreviations: CE, cholesterol 
esters; MUFA, monounsaturated fatty acids; PL, phospholipids; SCD1, stearoyl-CoA 
desaturase-1; SFA, saturated fatty acids; TAG, triacylglycerols. Reprinted with 
permission.
115
 
 
1.6 FATTY ACIDS, INSULIN RESISTANCE AND THE METABOLIC 
SYNDROME 
MetS currently affects approximately 25% of the adult population.
116
 It increases the 
risk of CKD
46,117-120
 as well as mortality risk in CKD patients.
121
 IR is a key feature of 
MetS, in combination with other metabolic disorders.
116
 IR develops with the decline in 
GFR
47,122
 and, in turn, may predict a rapid progression of CKD.
120
 In addition, chronic 
low-grade inflammation is also closely connected with both MetS and IR, and have 
been suggested as an important causal factor for these glucometabolic derangements.
123
 
 
Studies in non-CKD populations suggest that energy-dense, high-fat diets promote IR 
and MetS.
124,125
 Dietary fat quality, rather than quantity, may be more important in 
increasing these risks: whereas SFA intake seems to aggravate MetS and IR 
126
, dietary 
n-6 PUFA from vegetable sources have been linked to improved insulin sensitivity and 
reduced risk of developing MetS and.
127,128
 Marine n-3 PUFA have also been 
associated with favorable effects on MetS, such as lowering of triglycerides,
129
 but 
evidence for improving insulin-glucose metabolism is weak.
130
 In the context of CKD, 
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whether fatty acids associate with IR and MetS is presently unknown. This issue is 
further developed in Study 4. 
 
1.7 FATTY ACIDS, CARDIOVASCULAR EVENTS AND SURVIVAL 
Results from observational studies addressing the association between fatty acids and 
outcomes in CKD patients are elusive.
131-133
 In one prospective cohort study, the 
consumption of fish in HD patients was associated with an approximately 50% lower 
rate of mortality over 3 years.
134
 Also, HD patients within the highest tertile of 
erythrocyte DHA content had a reduced mortality risk.135 In a recent nested case-
control study, a strong and independent association between higher n-3 PUFA levels 
and a lower risk of sudden cardiac death throughout the first year of dialysis in incident 
HD patients was observed.136 However, another study in prevalent HD patients did not 
find a significant association between erythrocyte n-3 PUFA proportions and 
mortality.
137
 This negative result is in line with results from a study using dietary n-3 
PUFA estimations in HD patients
94
 Dietary modifications towards high n-3 PUFA 
intake have the potential to reduce mortality in populations at high CVD risk. Two 
large RCT, the GISSI-Prevenzione
138
 and JELIS trials,
139
 showed that n-3 PUFA 
supplementation was associated with a significant reduction in deaths from cardiac 
causes in non-CKD populations. Yet, in renal patients, only two trials investigated the 
potential of n-3 PUFA supplementation to reduce hard endpoints. The OPACH study 
showed that n-3 PUFA supplementation significantly reduces the number of 
myocardial infarctions as a secondary outcome in HD patients.
140
 Similarly, the FISH 
study observed that fish oil supplementation improves cardiovascular event-free 
survival and thrombotic events as secondary outcomes in patients with new synthetic 
arteriovenous HD grafts.
141
 
 
There has been emerging evidence on the association between n-6 PUFA (specifically 
LA) and mortality in the general population.
142-147
 Nonetheless, no studies to date 
investigated this relationship in CKD patients. The association between these essential 
fatty acids (LA, EPA and DHA) and mortality in dialysis patients is further developed 
in Study 2. 
 
Considering its risk implications on excess body and liver fat deposition,
114,148
 
hypertriglyceridemia,
149
 IR,
150
 diabetes mellitus (DM),
151
 inflammation,
104,105
 and 
endothelial dysfunction,
105
 it is plausible to hypothesized that increased SCD-1 activity 
   9 
may increase risk of mortality. Data from a community-based cohort indeed suggests 
so.
145
 However, the mortality predictability of SCD-1 has not been explored in CKD. 
This association is further developed in Study 3. 
 10 
2 AIMS 
The overall aim of this thesis was to increase our understanding of circulating fatty 
acids as a reflection of dietary intake in patients with CKD, with special emphasis on 
their clinical determinants and outcome implications. 
 
The specific aims were: 
 To identify fatty acids in serum cholesterol esters and adipose tissue that are 
adequate biomarkers of habitual intake in individuals with CKD (Study 1). 
 To investigate the implications of circulating essential PUFA, as a reflection of 
long-term dietary intake, on the inflammatory risk profile and clinical outcome of 
dialysis patients (Study 2). 
 To investigate clinical determinants and outcome implications of estimated 
hepatic and adipose tissue SCD-1 activities in dialysis patients (Study 3). 
 To assess cross-sectional relationships between serum fatty acid patterns, the 
metabolic syndrome, insulin sensitivity and inflammation in individuals with 
moderate CKD (Study 4). 
   11 
3 MATERIALS AND METHODS 
3.1 PARTICIPANTS 
This thesis was developed with data obtained from three observational cohorts: the 
Malnutrition, Inflammation, and Atherosclerosis 1 year (MIA-1), the Uppsala 
Longitudinal Study of Adult Men (ULSAM), and the Prospective Investigation of the 
Vasculature in Uppsala Seniors (PIVUS) cohorts. MIA-1 had been coordinated by the 
Division of Renal Medicine, Department of Clinical Sciences, Intervention and 
Technology, Karolinska Institutet. Patient phenotype was analyzed post hoc using 
collected data and, when necessary, by making new analyses from frozen samples. 
ULSAM and PIVUS studies were performed in collaboration with Uppsala University, 
which is responsible for cohort collection and management. 
 
3.1.1 MIA-1 
The MIA cohort is an ongoing patient cohort described in detail elsewhere.
44
 Briefly, 
434 ESRD patients with GFR <15 mL/min/1.73m
2
, enrolled at Karolinska University 
Hospital at Huddinge from 1994 to 2009, were evaluated close to the start of dialysis 
and were followed prospectively. Exclusion criteria included age <18 or >70 or 75 
years, signs of overt infection, and unwillingness to participate. These patients were 
then invited to perform a second clinical assessment after approximately one year of 
dialysis therapy. Patient recruitment occurred between April 1996 and October 2010. 
From 434 patients included, 255 attended the second visit, comprising the MIA-1 
cohort. Reasons for not attending the second assessment included death (n=45), kidney 
transplantation (n=58) and unwillingness or inability to participate (n=76). 
 
3.1.2 ULSAM 
ULSAM is a community-based cohort initiated in 1970; all 50-year-old men born 
between 1920 and 1924 and living in Uppsala, Sweden, were invited to a health survey 
at the Department of Public Health and Caring Sciences/Geriatrics, Uppsala University  
(described in detail at http://www.pubcare.uu.se/ULSAM/). Participants returned for 
subsequent examinations at age 60, 70, 77, and 82 years. This thesis was based on the 
third examination cycle of the ULSAM cohort, when participants were approximately 
70 years of age (visits performed during 1991 to 1995; n=1221). 
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3.1.3 PIVUS 
PIVUS is a community-based cohort initiated in 2001 at the Department of Medicine, 
Uppsala University (described in detail at http://www.medsci.uu.se/pivus/). All 70-
year-old individuals living in Uppsala, Sweden, between 2001 and 2004 were eligible 
for the PIVUS study. A random sample of 1016 subjects was included with the primary 
aim to investigate the predictive power of different measurements of endothelial 
function and arterial compliance. 
 
3.2 STUDY PROTOCOLS 
Because of specific exclusion criteria in each study and some missing values of the 
main outcomes assessed (due to impossibility to make an assessment or lack of plasma 
available), the number of individuals and main parameters considered in each of the 
studies vary as summarized in Table 3. 
 
Table 3. Basic description of the individual studies. 
Note: Abbreviations: AT, adipose tissue; CE, cholesterol esters; CRP, C-reactive 
protein; HOMA-IR, homeostasis model of assessment - insulin resistance; IL-6, 
interleukin-6; MIA-1, Malnutrition, Inflammation, and Atherosclerosis 1 year; PIVUS, 
Prospective Investigation of the Vasculature in Uppsala Seniors; PL, phospholipids; 
PUFA, polyunsaturated fatty acids; SCD-1, stearoyl-CoA desaturase-1; ULSAM, 
Uppsala Longitudinal Study of Adult Men. 
 
3.2.1 Study 1 
This is a cross-sectional analysis including individuals with a serum cystatin C-
estimated GFR <60 mL/min/1.73m
2
 (n=543) from the ULSAM cohort. Exclusion 
criteria were incomplete data on 7-day dietary records (n=36) and abnormal values of 
reported energy intake (<3200 or >18,000 kJ/d; n=1). Study 1 therefore comprises 506 
participants with CKD according to the current Kidney Disease Outcomes Quality 
Initiative definition.
1
 Fatty acid compositions of serum cholesterol esters and adipose 
Study Cohort Subjects Exposure Outcome 
1 ULSAM 506 Dietary fatty acid intake Fatty acid compositions 
of serum CE and AT 
2 MIA-1 222 PUFA in plasma PL IL-6, all-cause 
mortality 
3 MIA-1 222 Estimated hepatic and 
AT SCD-1 activities 
IL-6, all-cause 
mortality 
4 ULSAM 
PIVUS 
274 
187 
Serum fatty acid 
patterns 
Metabolic syndrome, 
glucose disposal, 
HOMA-IR, CRP 
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tissue were analyzed in two random sub-samples of 248 and 318 CKD men, 
respectively. The Ethics Committee of Uppsala University, Sweden, approved the study 
(Dnr 251/90). 
 
3.2.2 Study 2 
This is a prospective observational study using data from the MIA-1 cohort. From the 
255 MIA-1 dialysis subjects, we excluded 6 patients with “dialysis vintage” (preceding 
time on dialysis) <4 or >18 months and 26 additional patients without sufficient plasma 
for fatty acid analysis. No differences were observed in general and demographic 
characteristics between the included 223 patients and non-included patients. After fatty 
acid analysis was performed, one patient was excluded due to inconsistent 
chromatographic results a priori. Study 2 therefore comprises 222 dialysis patients. The 
Ethics Committee of Karolinska Institutet, Sweden, approved the study (Dnr 008/98, 
415/03, 2010/1112). 
 
3.2.3 Study 3 
This is a prospective observational study using data from the MIA-1 cohort. Similar to 
Study 2, 222 dialysis patients were included in this analysis. However, in Study 3, 
additionally two patients were excluded due to inconsistent chromatographic results of 
free fatty acid composition. Thus, the analysis related with FFA included 220 dialysis 
patients a priori. The Ethics Committee of Karolinska Institutet, Sweden, approved the 
study (Dnr 008/98, 415/03, 2010/1112). 
 
3.2.4 Study 4 
This is a cross-sectional analysis including individuals with CKD from two 
independent community-based cohorts: the ULSAM and PIVUS studies. In ULSAM, a 
total of 543 individuals were identified as having CKD on the basis of a cystatin C-
estimated GFR <60 mL/min/1.73m
2
 in accordance with the current Kidney Disease 
Outcomes Quality Initiative.
1
 Fatty acid composition of serum cholesterol esters was 
available in 274 individuals who were included in the present analysis. In PIVUS, a 
total of 187 PIVUS individuals with a cystatin C based GFR <60 mL/min/1.73m
2
 were 
included in the present analysis, and data on fatty acid composition of serum 
cholesterol esters was available in all of them. The Ethics Committee of Uppsala 
University, Sweden, approved the study (Dnr 251/90, 00-419, 2011/045, 2011/045/1). 
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3.3 METHODS 
3.3.1 Clinical examination 
All investigations were performed under standardized conditions as described 
elsewhere.
44,152,153
 Body mass index was calculated as the ratio of the body weight (in 
kg) to the height (in m
2
). Waist circumference was measured midway between the 
lowest rib and the iliac crest. Smoking status was defined as smoking versus 
nonsmoking. Regular physical activity was defined as the reporting of regular or 
athletic leisure-time exercise habits according to four physical activity categories 
(sedentary, moderate, regular, and athletic).
154
 Supine blood pressure was measured 
twice in the right arm after 10 minutes’ rest, and means were calculated. Subjective 
global assessment (SGA) was used to evaluate the overall nutritional status. SGA relies 
on clinical judgment accrued from grading scales calculated from a brief history and 
physical examination.
155
 The history examination focuses on gastrointestinal symptoms 
(anorexia, nausea, vomiting and diarrhea) and weight loss in the preceding 6 months. 
The physical examination includes loss of subcutaneous fat over the triceps and mid-
axillary line of lateral chest wall, muscle wasting in the deltoids and quadriceps, and the 
presence of ankle edema. These features are classified as 0 = normal, l = mild, 2 = 
moderate, 3 = severe. On the basis of a weighing of these data, patients are classified 
into two groups: normal nutritional status, with a SGA score = 1; and PEW, with a 
SGA score >1.
156
 
 
Previous CVD was defined as history of any CVD as recorded in the Swedish Hospital 
Discharge Registry [International Classification of Diseases (ICD-8) codes 390 to 458 
or ICD-9 codes 390 to 459]. DM was defined as fasting plasma glucose ≥7.0 mmol/L, 
2-hour postload glucose levels ≥11.1 mmol/L, or the use of oral hypoglycemic agents 
or insulin.
157
 Hypertension was defined as systolic blood pressure ≥140 mmHg, 
diastolic blood pressure ≥90 mmHg, or use of antihypertensive medications. 
Hyperlipidemia was defined as serum cholesterol >6.5 mmol/L and/or serum 
triglycerides >2.3 mmol/L and/or treatment with lipid-lowering medications. We 
adopted the modified National Cholesterol Education Program Adult Treatment Panel 
III (NCEP: ATP III) criteria, with three or more of the following criteria being defined 
as MetS:
116
 (1) abdominal obesity: waist circumference >102 cm for men, >88 cm for 
women; (2) hypertriglyceridemia: serum triglycerides ≥1.7 mmol/L or on lipid 
lowering drug treatment; (3) decreased high-density lipoprotein (HDL): serum HDL 
concentrations <1.04 mmol/L for men, <1.3 mmol/L for women, or on lipid lowering 
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medication; (4) hypertension: systolic blood pressure ≥130 mmHg or diastolic blood 
pressure ≥85 mmHg or under anti-hypertensive drug treatment, and; (5) hyperglycemia: 
fasting plasma glucose concentrations ≥5.6 mmol/L or on anti-glycemic medication or 
previously diagnosed type 2 DM. 
 
3.3.2 Dietary assessment 
In ULSAM, dietary habits were evaluated with an optically readable form of a 7-day 
dietary record based on a validated pre-coded menu book,
158
 which was prepared and 
previously used by the Swedish National Food Administration.
159
 The participants were 
given oral instructions by a dietitian on how to perform the dietary registration, and the 
amounts consumed were reported in household measurements or specified as portion 
sizes. The daily intake of energy, various fatty acids, fish, and alcohol was calculated 
by using a database from the Swedish National Food Administration. This method 
permitted estimation of the intake of major specific fatty acids, e.g., palmitic and stearic 
acids in the SFA class. Fatty acid intake was expressed in two different ways: as 
absolute intake (g/d), and as a percentage of total fat intake by weight [(g/g total fat) * 
100], with the latter being comparable with biomarker measurements. 
 
Stringent criteria to identify adequate reporters of energy intake were applied according 
to the Goldberg cut-off.
160
 In this procedure, an acceptable range of energy intake is 
determined for each subject in relation to estimated energy expenditure taking the level 
of physical activity and calculated basal metabolic rate into consideration, i.e., 
producing a 95% confidence interval for energy intake required for weight maintenance. 
Subjects with reported energy intake within the 95% confidence interval were regarded 
as adequate reporters, rendering a subpopulation of 250 individuals for verification of 
the associations reported in the whole material (n=506). 
 
3.3.3 Laboratory analyses 
After an overnight fast, blood samples were obtained. Plasma and serum were 
separated and kept frozen at -70°C, if not analyzed immediately. In the MIA-1 study, 
triglyceride, total cholesterol, HDL, high-sensitive C-reactive protein (CRP), and 
albumin concentrations were analyzed using certified methods in the Department of 
Laboratory Medicine at Karolinska University Hospital. The Friedewald equation
161
 
was used to calculate LDL from total cholesterol, HDL, and triglyceride. Serum 
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concentrations of interleukin (IL)-6 were quantified by immunometric assays on an 
Immulite Analyzer (Siemens Medical Solutions Diagnostics, Los Angeles, CA, USA). 
 
In ULSAM and PIVUS, the assays were performed at the Department of Clinical 
Chemistry, University Hospital, Uppsala, which is accredited according to the Swedish 
Board for Accreditation and Conformity Assessment (Swedac) standard ISO/IEC 
17025. Serum triglyceride and HDL concentrations were assayed by enzymatic 
techniques. Fasting blood glucose concentration was determined by an oxidase method 
and insulin by radioimmunoassay. CRP measurements were performed by latex 
enhanced reagent (Dade Behring, Deerfield, IL, USA) using a Behring BN ProSpec 
analyzer (Dade Behring). Serum cystatin C (ULSAM: N Latex Cystatin C, Dade 
Behring, Deerfield, IL, USA; PIVUS: Gentian, Moss, Norway) was used to estimate 
GFR.
162,163
 Individuals with CKD were further divided into stage 3A and more 
advanced stage of CKD on the basis of a GFR cut-off value of 45 mL/min/1.73m
2
. 
Urinary albumin excretion rate (UAER) was calculated on the amount of albumin in the 
urine collected during the night. The assay employed a commercially available 
radioimmunoassay kit (Albumin RIA 100, Pharmacia, Uppsala, Sweden). 
Microalbuminuria was defined as UAER ≥30 mg/24h. 
 
3.3.4 Fatty acid compositions and desaturase activities 
Fatty acid compositions of plasma phospholipids (MIA-1), FFA (MIA-1), serum 
cholesterol esters (ULSAM and PIVUS), and adipose tissue (PIVUS) were analyzed by 
gas-liquid chromatography (GLC) at the Unit for Clinical Nutrition Research, 
Department of Public Health and Caring Sciences, Uppsala University, Uppsala, 
Sweden. Subcutaneous AT was collected with biopsy from the upper, outer quadrant of 
the buttocks.
164
 The samples were stored at -70°C for some weeks until analyses. 
 
As previously described,
165
 an extraction with chloroform was conducted. The dry 
extracts were dissolved in a few drops of chloroform and applicated on thin liquid 
chromatography plates for separation of the lipids. The lipid esters were trans-
methylated and the methyl esters were extracted. The fatty acid methyl esters were 
dissolved in hexane and separated by GLC. The Hewlett Packard GLC system used for 
the analyses was consisted a GC 5890, automatic sampler 7671A, integrator 3392A, 
and 25 m Quadrex Fused Silica capillary column OV-351. The fatty acids were 
identified by comparison of the retention times of separation was controlled by Nu 
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Check Prep GLC reference standard GLC-68A. The coefficients of variation (CV) for 
all fatty acids were 1–5.5%, except for stearic acid, with a CV of 9.9%.166 Fatty acids 
are given as the relative percentage of the sum of the fatty acids analyzed. 
 
Direct measurement of SCD-1 activities in humans is complicated and not feasible in 
large cohort studies.
110,167
 We therefore estimated hepatic and adipose tissue SCD-1 
activities by using product-to-precursor fatty acid ratios (palmitoleic acid/palmitic acid). 
Preceding studies show a high degree of correlation between serum fatty acid 
biomarker-derived indices and tissue-derived indices, both liver and adipose tissue, 
with correlation coefficients of 0.86
168
 and 0.63,
169
 respectively. The palmitoleic 
acid/palmitic acid ratio (16:1 n-7/16:0) is preferred over the ratio oleic acid/stearic acid 
(18:1 n-9/18:0), since the latter is biased by high dietary intake of oleic acid.170 Dietary 
intake of palmitoleic acid, on the other hand, is very low in a Western-type Swedish 
diet and mostly represents a small amount of dietary fats in a typical Swedish diet.
171
 
Thus, plasma palmitoleic acid is almost exclusively derived from endogenous 
conversion from palmitic acid by SCD-1 and, in the present study, palmitoleic 
acid/palmitic acid was determined in plasma phospholipids and FFA to reflect SCD-1 
activities in the liver and in adipose tissue, respectively.
113,169
 
 
 
3.3.5 Insulin resistance 
We used both the euglycemic hyperinsulinemic clamp technique and homeostasis 
model of assessment - insulin resistance (HOMA-IR) to evaluate IR in the ULSAM 
cohort, while IR in the PIVUS cohort was solely assessed by the latter. Insulin 
sensitivity, i.e., assessed as the insulin-mediated glucose disposal (M) was estimated by 
euglycemic clamp as described by DeFronzo et al.,
172
 slightly modified with insulin 
(Actrapid Human, Novo, Copenhagen, Denmark) being infused at a constant rate of 56 
mU/body surface area (m
2
)/min during 120 minutes. This rate was estimated to 
suppress hepatic glucose output almost completely also in participants with type 2 DM. 
The target plasma glucose concentration was 5.1 mmol/L. M was calculated as the 
amount of glucose per kg of body weight (bw) taken up during the last 60 minutes of 
the study and expressed as mg/kg bw/min. HOMA-IR was computed with the formula: 
fasting plasma glucose (mmol/L)*fasting serum insulin (mU/L)/22.5.
173
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3.3.6 Follow-up 
All patients in the MIA-1 cohort were prospectively followed-up for up to 5 years, or 
until April 30
th
, 2011, death or kidney transplantation, whichever event occurred first. 
Causes of death were extracted from medical records by a physician blind to the study 
results. Death due to CVD included: fatal myocardial ischemia or infarction, cardiac 
arrest or unknown sudden death, acute as well as chronic heart failure, cerebrovascular 
accidents, cerebral hemorrhage, and ruptured aortic aneurysm. 
 
3.3.7 Statistical analysis 
Values were expressed as mean ± standard deviation, median (interquartile range; IQR) 
or percentage of total, as appropriate. Logarithmic transformation was applied for non-
normally distributed continuous valuables. All tests were two-tailed and P <0.05 was 
considered significant. Because P values were not adjusted for multiple testing, they 
have to be considered as descriptive. All statistical analyses were performed using 
statistical software STATA version 12 (Stata Corporation, College Station, TX, USA). 
 
Comparisons between the two groups were evaluated by the Student’s unpaired t tests 
for normally distributed continuous variables, the nonparametric Mann–Whitney tests 
for non-normally distributed continuous variables, and χ2 tests for nominal variables. 
 
As many values were not normally distributed, Spearman’s rank correlation was used 
to determine univariate correlations. Multivariable linear or logistic regression analyses 
were performed to assess independent associations, after the adjustment of potential 
confounders. Data are presented as standard coefficients (std. beta) or odds ratios, as 
well as 95% confidence intervals. 
 
Because kidney transplantation and death before transplantation are mutually exclusive 
events, i.e., the occurrence of either one prevents the occurrence of the other, traditional 
Cox regressions may be biased; we therefore calculated the cumulative incidence of 
death before kidney transplant using the competing risk approach.
174
 Data are presented 
as hazard ratios and 95% confidence intervals. 
 
Other specific statistical analyses are discussed in each of the studies presented in this 
thesis. 
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4 MAIN RESULTS AND DISCUSSION 
4.1 STRENGTHS AND LIMITATIONS 
4.1.1 Strengths 
This thesis has a number of strengths, starting with the detailed phenotype of our 
patient materials. The use of fatty acid compositions is an asset, as it avoids the 
problems of under-/over-reporting of dietary recalls. Factor analysis further captures 
inner relationships between the spectrum of fatty acids, grasping the concept of dietary 
fat quality and facilitating the interpretation of findings. Gold standard methods, i.e., 
fatty acid composition of adipose tissue
175
 and the euglycemic clamp technique,
172
 
improve the validity of the data. The 7-day dietary record is the most preferred dietary 
assessment method, and the use of Goldberg cut-offs to control for reporting bias 
represents a further strength.
77
 Another advantage is a long follow-up time without any 
patient being lost to follow-up. Also, we corrected in survival analyses for the 
competing risk of transplantation; restoration of renal function cancels the prospective 
risk of dying. Lastly, we in the present thesis focus on either essential fatty acid 
biomarkers (representing their dietary intake) or non-essential fatty acids (representing 
endogenous metabolism) in specific research questions a priori. This approach is 
biologically reasonable, since circulating fatty acids, even within a same biochemical 
family (SFA, MUFA, n-3 and n-6 PUFA), can be derived from distinct sources and 
may not be metabolically equivalent.
78,176
 Consistent with this concept, fatty acids 
expressed as these groups or ratios (PUFA/SFA and n-6/n-3 PUFA) used in some 
previous studies may be neither useful nor relevant in humans,
78,177
 and is not supported 
by RCT.
178,179
  
 
4.1.2 Limitations 
Our results should be interpreted considering the studies’ limitations. First of all, the 
cross-sectional nature of analyses does not allow inferring causality from the results. 
However, in studies on etiology, diagnosis, prognosis, or adverse effects, observational 
studies are more valid than RCT.
180
 Second, although the inclusion of individuals with 
similar both age/dialysis duration and geographical distribution reduces important 
confounding, our results may not necessarily be extrapolated to the general 
CKD/dialysis population. Third, there may be unmeasured or unknown confounders we 
cannot take into account, i.e., residual confounding. In this regard, we did not have 
information regarding the possible intake of fish oil supplements. Fourth, although 
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serum fatty acids can be used as indicators of dietary intake, some fatty acids are 
subjected to endogenous conversion.
113
 Circulating fatty acids may also represent the 
intake of certain foods that can contain other beneficial nutrients, e.g., fiber, which may 
contribute to the observed effects.
57
 Thus, the lack of dietary intake data to corroborate 
the biomarkers (MIA-1) is acknowledged as a limitation. Finally, in Study 3, we rely on 
estimations of SCD-1 indices, though they are considered to reflect hepatic and adipose 
tissue SCD-1 activities accurately
168,169
 and have been widely adopted.
169,181-183
 
Nonetheless, direct measurement of SCD-1 activities in humans is complicated and not 
feasible in large cohort studies.
167
 
 
There are further limitations from a statistical point of view. Our sample sizes are 
relatively small and the number of events in survival analysis is limited, potentially 
introducing type II (false negative) errors in decisions for which our patient materials 
were not adequately powered. We should also acknowledge the possibility of type I 
(false positive) errors in the case of random findings due to multiple testing. Because P 
values were not adjusted accordingly, they have to be considered as descriptive. 
Nonetheless, the fact that we mostly performed hypothesis-driven tests could somewhat 
reduce this possibility as an explanation to our findings and, importantly, the replication 
of our findings in an independent cohort (Study 4) would argue against type 1 error. In 
some cases, we might have introduced risk of over-adjustment.
184
 We have applied a 
shrinkage factor with Firth correction
185,186
 in Study 1 and tried, to our best, to avoid the 
impact of collinearity by adjusting for factors pathophysiologically unrelated.
187
  
 
4.2 FATTY ACID COMPOSITIONS AS BIOMARKERS OF HABITUAL 
INTAKE 
In Study 1, we showed that LA and DHA in serum cholesterol esters were strongly 
correlated with their corresponding intake in individuals with CKD stage 3-4, as 
presented in Figure 3. Palmitic acid and EPA presented moderate β values. On the 
other hand, stearic acid, ALA and arachidonic acid (20:4 n-6) were not associated with 
the dietary intake whilst oleic acid was negatively correlated with its proportion in the 
diet. In adipose tissue, the correlations with dietary fatty acids were similar, except that 
ALA was moderately associated, and oleic acid was not significantly associated, with 
their counterparts in dietary records. The strength of the associations between dietary 
fatty acids and their corresponding cholesterol ester and adipose tissue biomarkers were 
maintained or even improved in the subpopulation of adequate reporters. 
   21 
 
 
Figure 3. Relations between individual fatty acid proportions in dietary records versus 
serum cholesterol esters (CE) and adipose tissue (AT) respectively, expressed as 
standard coefficients (β) in multivariable regression models, both in all individuals with 
chronic kidney disease as well as in adequate reporters only. Models were adjusted for 
body mass index, smoking, alcohol intake, physical activity, cardiovascular disease, 
diabetes, hypertension, hyperlipidemia, estimated glomerular filtration rate, and urinary 
albumin excretion rate. Reprinted with permission.
188
 
 
For non-essential fatty acids, the relationships between individual fatty acid proportions 
in dietary records and both serum cholesterol ester and adipose tissue compositions 
were weaker or absent (Figure 3), accordant with those in populations without CKD.
79-
81,189
 However, palmitic acids were fairly good markers of dietary intake in the current 
population, although less strongly correlated than observed for LA and DHA. The 
correlations of SFA are weakened partly due to the fact that endogenous metabolism, 
including de novo lipogenesis (DNL), elongation and desaturation, affects the levels of 
these fatty acids.
76
 Apart from diet, SFA generated from carbohydrates through the 
process of DNL is another source of palmitic and stearic acids in the blood and tissues. 
In Western populations with relatively high fat intake, however, that DNL dilutes SFA 
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pools has been considered to be of minor importance.
76
 Furthermore, SCD-1 both in the 
liver and adipose tissue converts palmitic and stearic acids to synthesize palmitoleic 
and oleic acids, with oleic acid being the preferred substrate.
167
 It is therefore not 
surprising that there was a lack of direct association with the major MUFA oleic acid. 
The significantly negative association of oleic acid was however unexpected and 
difficult to explain. One might speculate that hepatic SCD-1 activity is suppressed in 
response to high intake of PUFA,
114
 food sources of which also contain substantial 
amounts of oleic acid.
76
 It is thus possible that high intake of vegetable oils (partly 
represented as high dietary oleic acid content) may in turn inhibit endogenous synthesis 
of oleic acid, thereby decreasing its levels in the body, and vice versa. 
 
As expected from its biology, the relationships between dietary intake and biomarkers 
for most essential PUFA were indeed the strongest in our study. This agrees with 
similar reports in non-CKD individuals,
79,80
 and these biomarkers can be used as 
indicators of compliance in supplementation studies.
114,190-192
 However, for ALA, we 
did not observe strong associations between dietary fatty acid intake and the biomarker, 
not even when considering adequate reporters. These results were unexpected and the 
reason is unclear, but in similar studies the agreement of ALA seems also poorer than 
for the other essential PUFA.
79,81
 The smaller proportion of ALA and the relatively 
higher within-person variability in its measurement may have contributed to these 
results. 
 
 
Figure 4. Mean eicosapentaenoic acid (20:5 n-3) and docosahexaenoic acid (22:6 n-3) 
proportions in serum cholesterol esters (CE) and adipose tissue (AT) according to daily 
fish intake (energy adjusted) quartiles. Bars represent standard errors. P for trend <0.01 
for all. Modified from.
188
 
 
As shown in Figure 4, total energy intake adjusted daily fish intake was positively 
associated with the proportions of EPA and DHA in cholesterol esters (β =0.21 and 
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0.26) and adipose tissue (β =0.18 and 0.18). Such findings are consistent with a 
previous report showing a positive association between the frequency of fish servings 
and n-3 PUFA index (the sum of erythrocyte EPA and DHA contents) in 75 HD 
patients.
62
 This suggests that dietary fish intake is a proxy of EPA and DHA intake in 
this population. 
 
We also found that the associations between dietary and biomarker fatty acids held 
constant across eGFR (above and below 45 mL/min/1.73m
2
) or UAER (above and 
below 30 mg/24h) groups, suggesting that moderate renal failure does not modify the 
associations. Likewise, one previous investigation indicates that the status of other 
chronic diseases, e.g., CVD, hypertension and DM, does not modify these relationships 
either.
79
 Nevertheless, we must take into consideration that the included patients were 
mostly within CKD stage 3, and further studies may be necessary including patients 
with a broader GFR distribution. 
 
In summary, our results suggest that LA, EPA, DHA, and palmitic acid in serum 
cholesterol esters and adipose tissue are good indicators of the habitual dietary intake of 
fatty acids in elderly men with CKD. Dietary fish intake well reflect intake of n-3 
PUFA of marine origin in this population. The weak or lack of association with other 
fatty acids limits their use as biomarkers and thus fatty acid composition does not 
capture the intake of all fatty acids. Taken together, specific fatty acid biomarkers could 
be a valid and objective tool to use in epidemiological studies which aim at linking 
dietary fat quality and diet-related conditions in CKD. At the same time, they can be 
considered to measure compliance in dietary intervention studies. 
 
4.3 FATTY ACIDS AND INFLAMMATION 
In Study 2, we observed a negative relationship between plasma LA and IL-6 in 
dialysis patients (Figure 5). An opposite association was found for Mead acid, whose 
elevation in the blood is regarded as an indication of LA deficiency.
193
 Results in Study 
4 also confirm this concept: in two independent cohorts of elderly individuals with 
moderate CKD, a serum fatty acid pattern (generated by factor analysis with a varimax 
rotation) representing low LA/high SFA was strongly and independently associated 
with CRP. 
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Figure 5. Correlations between linoleic acid, Mead acid and serum interleukin-6 
concentrations in 222 dialysis patients. Reprinted with permission.
194
 
 
These findings are in agreement with previous community reports showing that the 
plasma level of LA inversely correlated with pro-inflammatory biomarkers.
104-107
 
Notably, a recent RCT in abdominally obese individuals showed that dietary 
substitution of butter (SFA-rich) by sunflower oil (LA-rich) improves inflammatory 
status in compliant individuals.
114
 Data on effects of n-6 PUFA supplementation in 
CKD patients are almost nonexistent, with only Begum et al.96 demonstrating a trend 
toward a decrease in leukotriene B4 (a pro-inflammatory eicosanoid) production. LA 
suppresses the production of adhesion molecules, chemokines, and interleukins in 
vitro.195 Arachidonic acid, one of the LA metabolites, is also favorably linked with 
circulating pro-inflammatory and anti-inflammatory markers in humans.
107
 SFA can 
directly cause inflammation; they increase the expression and secretion of 
inflammatory cytokines
88-90,196
 and induce nuclear factor-kappa B activation.
91
 
 
In Study 3, SCD-1 indices in both plasma phospholipids and FFA, reflecting the 
enzyme activities in the liver and adipose tissue, were directly correlated with IL-6 in 
dialysis patients, as shown in Figure 6. Such a link is supported by findings in animals, 
cell studies
197,198
 and community-based cohorts.
104,105
 Since SCD-1 increases in 
response to dietary SFA intake,
113
 these observations also support the notion that SFA 
have pro-inflammatory functions as aforementioned. However, SCD-1 per se may also 
cause inflammation in liver and adipose tissue,
197
 a finding supported by observations 
from SCD-1 knockout mice which are protected from inflammation in macrophages, 
endothelial cells, and adipose tissue.
198
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Figure 6. Correlations of stearoyl-CoA desaturase-1 (SCD-1) activity indices in plasma 
phospholipids (PL) and free fatty acids (FFA) with serum interleukin-6 concentrations 
in dialysis patients. Modified from.
199
 
 
We did not observe an association between circulating n-3 PUFA and inflammatory 
markers in CKD (Study 4) and dialysis patients (Study 2). However, this is in 
agreement with findings in Swedish community studies
104,105
 and with a previous 
American report in dialysis patients using n-3 PUFA intake estimated from dietary 
records.
94
 The absent relationship between n-3 PUFA and uremic inflammation may be 
explained by the stronger links that n-3 PUFA shared with PEW. Nevertheless, our 
results do not contradict the notion that supplementation with n-3 PUFA has the 
potential to reduce systemic inflammation in CKD patients.
133,200
 It has been reported 
that dialysis patients have reduced plasma n-3 PUFA levels62,201 and thereby, 
circulating levels may not suffice to exert their anti-inflammatory effects. In fact, 
clinical trials generally show that supplementation with n-3 PUFA has the potential to 
reduce inflammation (as summarized in Table 2), indirectly supporting the speculation 
from observational research that reduced circulating n-3 PUFA in dialysis patients exert 
few anti-inflammatory properties. On the other hand, it is also possible that, in the 
context of a Swedish diet where fish intake is relatively adequate compared with for 
instance that in an American diet,
63,171
 these links are thus not fully evident. Further 
studies in CKD populations should confirm these relationships. 
 
Taken together, these findings support the concept that LA may suppress while SFA 
may induce the CKD-related inflammatory status. 
 
 26 
4.4 FATTY ACIDS AND INSULIN RESISTANCE 
In Study 4, the fatty acid pattern representing low LA/high SFA strongly correlates 
with IR, depicted by low glucose disposal or high HOMA-IR values, in both ULSAM 
and PIVUS cohorts of CKD subjects (Figure 7). Consistent with our finding, earlier 
reports in non-CKD populations indeed showed that individuals with a low proportion 
of serum LA have impaired fasting glycemia
202
 and increased risk of developing 
DM.
151
 Also, interventional studies have shown that whereas a diet enriched in LA 
improves insulin sensitivity, a diet high in SFA is likely to result in IR.
126,170
 A recent 
study demonstrated that a diet rich in PUFA in insulin resistant men acutely reduces 
triacylglycerol-derived skeletal muscle fatty acid uptake, accompanied by improved 
postprandial insulin sensitivity.
203
 
 
In the PIVUS study, a factor representing high n-3 PUFA was positively linked with 
HOMA-IR. However, a similar result was not confirmed in ULSAM, by using either 
glucose disposal or HOMA-IR. The association of the high n-3 PUFA factor reported 
in PIVUS may be attributed to the fact that a moderate positive loading from 
arachidonic acid, which usually comes from dietary animal sources,
204
 was also present. 
Indeed, we did not observe such associations when EPA or DHA were studied 
individually. 
 
 
Figure 7. Correlations of low linoleic acid/high saturated fatty acid factors with glucose 
disposal in the Uppsala Longitudinal Study of Adult Men (ULSAM) cohort or with 
homeostasis model of assessment - insulin resistance (HOMA-IR) in the Prospective 
Investigation of the Vasculature in Uppsala Seniors (PIVUS) cohort. Participants (n=12 
in ULSAM and n=16 in PIVUS) on medication for diabetes (orally or via injections) 
were excluded in the analyses of glucose disposal and HOMA-IR. 
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4.5 FATTY ACIDS AND METABOLIC SYNDROME 
In Study 4, 68 (25%) and 61 (33%) CKD individuals in the ULSAM and PIVUS 
studies, respectively, met at least three NCEP: ATP III criteria and were considered to 
have MetS. Factor scores of the two derived factors (low LA/high SFA and high n-3 
PUFA factors) were plotted by the number of MetS components, as presented in 
Figure 8. Increasing scores of the low LA/high SFA factors in both cohorts were 
strongly and positively associated with the number of MetS components. A borderline 
increasing trend was revealed for the n-3 PUFA factor in PIVUS, but could not be 
confirmed in ULSAM. In multivariable logistic regression models (Table 4), every 
standard deviation decrease in the low LA/high SFA factors (thereby depicting an 
increase in LA intake and a reduction in SFA intake) reduced the odds to have MetS in 
the two studies. Likewise, across decreasing low LA/high SFA factor tertiles, the odds 
to have MetS were incrementally smaller. No significant relationship with MetS was 
observed 
 
Figure 8. Factor scores across increasing number of metabolic syndrome components 
in the Uppsala Longitudinal Study of Adult Men (ULSAM) and the Prospective 
Investigation of the Vasculature in Uppsala Seniors (PIVUS) cohorts. Data are 
presented as mean ± standard errors. Standardized coefficients (β) and P values for 
trend were derived from linear regression analyses. Abbreviations: LA, linoleic acid; 
PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids. 
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observed for scores of the n-3 PUFA factor in both cohorts. To test the robustness of 
these results and the representativeness of the generated factors, analyses were repeated 
using single fatty acid proportions (proportions of serum cholesterol ester LA, EPA, 
and DHA). LA as a single fatty acid was negatively associated, while EPA and DHA 
were not associated, with the presence of MetS in the two cohorts. 
 
The MetS strongly predicts total and cardiovascular mortality in the community
205
 as 
well as in individuals with CKD.
121
 MetS may also represent a risk factor for 
CKD.
46,119,121
 Our current results are of clinical interest since we identified links 
between modifiable dietary fat patterns and the presence of MetS in high-risk 
individuals with impaired renal function. Strengthening this observation, we also found 
strong associations between this dietary pattern, IR and inflammation, both key 
pathogenic links underlying the clustering of abnormalities in MetS.
116
 This finding is 
consistent with previous observations in the community and in individuals with DM, 
CVD or MetS.
127,128
  
 
Table 4. Multivariable logistic regression models predicting for the presence of the 
metabolic syndrome in individuals with chronic kidney disease according to the 
generated serum fatty acid patterns. 
Note: All models were adjusted for smoking status, physical activity, and estimated 
glomerular filtration rate and, in the PIVUS cohort, also sex. Abbreviations: CI, 
confidence interval; LA, linoleic acid; OR, odd ratio; PIVUS, Prospective Investigation 
of the Vasculature in Uppsala Seniors; PUFA, polyunsaturated fatty acids; SD, standard 
deviation; SFA, saturated fatty acids; ULSAM, Uppsala Longitudinal Study of Adult 
Men. 
 
 
 OR (95% CI) 
 ULSAM PIVUS 
Factor 1 (Low LA/high SFA)   
Continuous (per SD decrement) 0.60 (0.44, 0.81) 0.45 (0.30, 0.67) 
Grouped as   
Low LA (high scores) Ref. Ref. 
Medium LA (medium scores) 0.52 (0.25, 1.06) 0.52 (0.24, 1.13) 
High LA (low scores) 0.22 (0.09, 0.51) 0.16 (0.06, 0.43) 
P for trend 0.002 0.001 
Factor 2 (High n-3 PUFA)   
Continuous (per SD increment) 0.84 (0.61, 1.15) 1.27 (0.91, 1.76) 
Grouped as   
Low n-3 PUFA (low scores) Ref. Ref. 
Medium n-3 PUFA (medium scores) 1.48 (0.72, 3.05) 0.65 (0.29, 1.47) 
High n-3 PUFA (high scores) 0.65 (0.29, 1.44) 1.06 (0.49, 2.30) 
P for trend 0.1 0.5 
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4.6 FATTY ACIDS AND MORTALITY 
Sixty-one (27%) dialysis patients in the MIA-1 cohort died during a median follow-up 
period of 18.4 (IQR: 5.5 - 37) months. The main causes of death were CVD-related (n 
=37, 61% of total deaths). One hundred and sixteen (52%) individuals underwent 
kidney transplantation. Due to the different biological interpretations of plasma fatty 
acids, we focused on essential fatty acids (as indicators of exogenous input) in Study 2 
and on non-essential fatty acids (as estimates of endogenous metabolism) in Study 3, 
respectively. 
 
In Study 2, each percentage of increase in the proportion of LA significantly reduced 
the mortality risk before kidney transplantation. Adjusting within the causal pathway 
(Model 2, plus IL-6 concentrations) did not modify the results (Table 5). The inverse 
association between circulating LA levels and the risk of all-cause mortality we 
observed adds to the growing evidence in the general population that an increase in 
circulating LA associates with reduced cardiovascular risk and improved outcomes.
142-
145
 Mead acid, whose elevation in the blood is regarded as an indication of LA 
deficiency,
193
 was directly associated with mortality, indirectly reinforcing the 
consequences of LA deficiency. Apart from the possible causal pathways we have 
discussed (inflammation, IR, and MetS), mechanisms by which LA may link to 
reduced 
Table 5. All-cause mortality risk before kidney transplantation (competing risk models) 
associated to proportions of plasma phospholipid polyunsaturated fatty acids (per 1% of 
increase) in 222 dialysis patients. 
Note: Because of small proportions, the levels of Mead acid and α-linolenic acid were 
multiplied by 10 to show meaningful risks estimates, thus depicting the risk associated 
to 0.1% increase; Model 1 is adjusted for sex, age, comorbidities (composite score of 
diabetes mellitus and cardiovascular disease), dialysis modality, and protein-energy 
wasting (by subjective global assessment); Model 2 is adjusted for factors detailed in 
Model 1 plus interleukin-6. No interactions (the polyunsaturated fatty acids * sex, the 
polyunsaturated fatty acids * dialysis modality, and the polyunsaturated fatty acids * 
protein-energy wasting) were observed. Abbreviations: CI, confidence interval; HR, 
hazard ratio; LC n-3, long-chain n-3 polyunsaturated fatty acids (the sum of 
eicosapentaenoic, docosapentaenoic, and docosahexaenoic acids). Reprinted with 
permission.
194
 
 
 HR (95% CI) 
 Crude Model 1 Model 2 
Linoleic acid 0.89 (0.81, 0.98) 0.88 (0.79, 0.98) 0.89 (0.79, 0.99) 
Mead acid (*10) 1.31 (1.08, 1.59) 1.35 (1.19, 1.52) 1.33 (1.17, 1.52) 
α-linolenic acid (*10) 0.93 (0.71, 1.23) 0.86 (0.63, 1.17) 0.89 (0.65, 1.23) 
LC n-3 0.89 (0.71, 1.11) 0.91 (0.72, 1.15) 0.91 (0.72, 1.16) 
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reduced mortality could include retarding the reduction of GFR,
82
 reducing liver fat,
114
 
as well as lowering of cholesterol
206,207
 and blood pressure.
208
  
 
As shown in Table 5, n-3 PUFA did not associate with mortality, a result which 
however agrees with findings from the general Swedish population where n-3 PUFA 
intake is relatively high
145
 but also with previous evidence in dialysis patients using 
either erythrocyte n-3 PUFA content137 or dietary-estimated n-3 PUFA.94 Kutner et 
al.134 reported that higher fish intake associated with decreased mortality risk in 
incident dialysis subjects. Divergences in results may be attributed to methodological 
issues (food frequency questionnaires vs. plasma PUFA content) as well as study 
design. Also, Hamazaki et al.135 showed that Japanese dialysis patients within the 
highest tertile of erythrocyte DHA content had a reduced mortality risk. Again, 
variances in the source of n-3 PUFA content between that and our study (erythrocyte vs. 
plasma phospholipids), the use of categories in studies with reduced sample size and 
especially the likely differences in fish intake between Swedish and Japanese 
populations, limit the relevance of comparisons. While further research is needed to 
confirm our results, regional, cultural and individual dietary differences may preclude a 
general conclusion regarding the association between PUFA and risk profile. Thus, our 
findings should be contemplated within the context of Western-type and Swedish diet. 
Despite the present study being the largest of its kind in dialysis patients, it should be 
noted that the magnitude of the reduced risk estimates was in fact similar between n-6 
and n-3 PUFA. 
 
In Study 3, due to the lack of clinically defined cut-off points for SCD-1 activity 
indices, we estimated them on the basis of receiver operator characteristic curve 
analyses for prediction of all-cause mortality. The clinical cut-off values of maximum 
sensitivity and highest specificity were used in further analyses to define high and low 
SCD-1 activities in this dialysis population. 
 
In the competing-risk Cox models presented in Table 6, patients with high 
phospholipid and FFA SCD-1 activity indices presented significantly higher mortality 
risk before kidney transplantation, as compared with those with low SCD-1 indices. 
Similar direct associations were observed when SCD-1 indices were tested as 
continuous variables. 
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Table 6. All-cause mortality risk before kidney transplantation (competing risk models) 
associated to stearoyl-CoA desaturase-1 activity indices in plasma phospholipids and 
free fatty acids in the dialysis patients. 
Note: In each lipid fraction, hazard ratios are presented either as categories 
(dichotomized into high and low SCD-1 according to ROC cut-off values -0.020 in 
phospholipids and 0.164 in free fatty acids-) or presented as a continuous variable 
depicting risk associated to each standard deviation increase. All models are adjusted 
for age, sex, comorbidities (composite score of diabetes mellitus and cardiovascular 
disease), dialysis modality, protein-energy wasting and interleukin-6. Abbreviations: CI, 
confidence intervals; HR, hazard ratios; SCD-1, stearoyl-CoA desaturase-1; SD, 
standard deviation. Modified from.
199
 
 
The strong and direct implication of both SCD-1 indices on mortality is in line with a 
previous Swedish community study, where hepatic SCD-1 index measured in serum 
cholesterol esters also predicted mortality.
145
 Reasons behind this association may 
involve deleterious effects associated with high SCD-1 activity, such as promotion of 
hepatic lipogenesis and steatosis,
209
 IR,
150,210
 endothelial dysfunction,
105
 and 
atherosclerosis.
211
 Because SCD-1 activity increases in humans in response to high 
SFA intake and low unsaturated fat intake,
113,114
 replacing palmitic acid or refined 
carbohydrates by MUFA or PUFA in the diet might be a useful dietary strategy to 
reduce SCD-1 activities. It is however unclear whether such an intervention could be of 
clinical importance, and it also remains to be shown in humans whether SCD-1 per se 
has adverse health effects. On the other hand, there is convincing evidence that 
replacing dietary palmitic acid by n-6 PUFA reduces cardiovascular events in 
humans.
212
 In this context it has been speculated that increased SCD-1 is an adaptive 
response to excess intake of SFA and/or sugars, and that such response will prevent 
toxic effects of high cellular levels of palmitic acid by converting it to MUFA.
167
 
 
To conclude, we find that both circulating LA level (inversely) and estimated SCD-1 
activities (directly) predict all-cause mortality in dialysis patients. Marine n-3 PUFA 
was not found associated with mortality risk in this population. 
 
Adjusted models 
HR (95% CI) P value 
Phospholipids (n=222)   
High SCD-1 index [reference: low] 2.29 (1.28, 4.11) 0.006 
SCD-1 index (per SD increase) 1.28 (1.00, 1.64) 0.05 
Free fatty acids (n=220)   
High SCD-1 index [reference: low] 2.36 (1.38, 4.03) 0.002 
SCD-1 index (per SD increase) 1.42 (1.19, 1.70) <0.001 
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5 CONCLUSIONS 
This thesis reports associations of circulating fatty acids and related biomarkers with 
the risk profile and outcomes in patients with CKD. The main conclusions are: 
 
1. LA, EPA, DHA, and palmitic acid in serum cholesterol esters and adipose tissue 
are good indicators of the habitual dietary fat intake in elderly men with CKD. 
Dietary fish intake reflects well the intake of n-3 PUFA of marine origin in this 
population. 
2. A serum fatty acid pattern reflecting low LA and high SFA is associated with 
inflammatory status, IR, and presence of MetS in CKD patients.  
3. Increased indices of hepatic and adipose tissue SCD-1 activities strongly correlate 
with inflammation in dialysis patients. 
4. Low circulating LA level predicts all-cause mortality in dialysis patients. 
5. Hepatic and adipose tissue SCD-1 activity indices are directly associated with 
mortality risk in dialysis patients. 
6. n-3 PUFA of marine origin (EPA and DHA) are not associated with inflammation, 
IR, the presence of MetS, or mortality in Swedish cohorts of individuals with 
CKD. 
The main findings of the thesis are schematically summarized in Figure 9. 
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6 DIRECTIONS OF FUTURE RESEARCH 
The present thesis attempts to shed light on a variety of possible connections and 
intriguing hypotheses that would, ultimately, lead to new therapeutic strategies in 
CKD. As the cross-sectional design of our studies precludes conclusions regarding 
causality, the next obvious steps would be to initiate longitudinal, interventional and 
mechanistic research attempts. 
 
Interestingly, results of n-3 PUFA in our Swedish cohorts presented in this thesis are 
neutral. n-3 PUFA levels differ substantially across regional and cultural areas
63
 and, 
in the context of CKD, other comorbidities such as PEW (a condition implicated in so 
called reverse epidemiology) may also complicate their risk implications. In future 
studies, all these differences ought to be taken into account to achieve a general 
conclusion regarding the association between n-3 PUFA and the CKD risk profile. 
 
Even though many interventional studies have tested the effects of n-3 PUFA/fish oil 
supplementation, particularly on proteinuria, blood lipoproteins, and inflammatory 
markers, a large number of them may not be sufficiently powered, not only due to the 
small sample size but also the relatively short duration. The turnover of fatty acids 
within each lipid pool and the incorporation of n-3 PUFA into the lipid pools occur at 
different rates.
78
 In future supplemental studies, one should thus prolong the duration 
as appropriate to capture changes of fatty acid composition, e.g., 2 months in 
erythrocyte membrane, and even longer for higher doses, and choose appropriate 
biomarkers to reflect varying periods of dietary intake of n-3 PUFA efficiently.213,214 
Also, gender differences,
215
 differential dose effect,
216
 and the interaction with n-6 
PUFA
217,218
 warrants attention. In CKD, specifically, the coexistence of high 
phosphate content in fish cannot be ignored. 
 
Our results raise the hypothesis that dialysis patients could benefit from increased 
intake of vegetable oils, the primary source of LA in the Western-type diet. Such 
strategies are being tested in non-CKD individuals and previous controlled trials 
suggest cardiovascular benefits when substituting SFA in the diet specifically for 
PUFA,
219
 effects mostly mediated by anti-hyperlipidemic mechanisms,
206
 but perhaps 
also by a reduction in liver fat and inflammation.
114
 For this reason, a science 
advisory from the AHA
146
 supports an n-6 PUFA intake of at least 5% to 10% of 
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energy in the context of other AHA lifestyle and dietary recommendations.
220
 
Whereas most RCT to date have been designed to investigate the effects of n-3 
PUFA,
133,200
 our data suggest that more research focus should be given to n-6 PUFA 
from vegetable oils in the context of CKD. In addition, other potential effects of LA 
are inconsistent or largely unknown.
82,83,221
 It would be attractive to investigate, for 
instance, whether it exerts reno-protective effects. 
 
We observed relationships of SCD-1 indices with inflammation and mortality risk, 
but it remains undetermined whether SCD-1 per se has adverse health effects in 
humans.
222
 SCD-1 may cause inflammation in liver and adipose tissue,
197
 a finding 
supported by observations from the SCD-1 knockout mouse.
198,210
 Nevertheless, 
increased SCD-1 activity may be an adaptive response to excess intake of SFA and/or 
sugars, and such response may prevent toxic effects of high cellular levels of palmitic 
acid by converting it to MUFA.
167
 In fact, the SCD-1 knockout mouse also develops 
severe vascular inflammation and atherosclerosis when exposed to a typical Western 
diet.
210
 Pharmacological inhibitors of the SCD-1, if available in the future, should be 
tested in a clinical setting, but with caution. An RCT replacing SFA with PUFA, 
while maintaining adequate protein and energy intake in CKD patients, is a less 
aggressive, but more feasible means. 
 
Previous research on dietary practice in the CKD population mainly focuses on single 
nutrients. Likewise, our studies in this thesis explore the role of fatty acids 
exclusively. Due to the complexity and intercorrelation of food components (we eat 
meals rather than isolated nutrients), however, dietary patterns may better capture 
inner relationships among nutrients and facilitate the interpretation of risk 
implications.
223
 The Mediterranean dietary pattern
224
 is increasingly gaining attention 
in the general population.
225
 We have found that adherence to this dietary pattern is 
associated with lower risk of CKD in a community-based cohort of elderly men and a 
greater adherence to this diet independently predicted better survival in those with 
manifest CKD (Huang et al. In submission). Future studies of this type, i.e., 
investigating the overall dietary quality, may be of greater practical relevance than 
studies focusing on single nutrients and should be encouraged. 
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